To further investigate the relationship of SOS1 and CML resistance, KCL-22 cells with BCR-ABL-independent imatinib resistance were developed by increasing the concentration of imatinib for a prolonged period. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.